The stock price of Viking Therapeutics Inc (NASDAQ: VKTX) has surged by 6.57 when compared to previous closing price of 73.22, but the company has seen a 18.59% gain in its stock price over the last five trading sessions. fool.com reported 2024-10-27 that Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.
Is It Worth Investing in Viking Therapeutics Inc (NASDAQ: VKTX) Right Now?
Company’s 36-month beta value is 1.00.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VKTX is 104.26M, and currently, short sellers hold a 13.81% ratio of that floaft. The average trading volume of VKTX on October 28, 2024 was 3.58M shares.
VKTX’s Market Performance
The stock of Viking Therapeutics Inc (VKTX) has seen a 18.59% increase in the past week, with a 25.21% rise in the past month, and a 27.40% gain in the past quarter. The volatility ratio for the week is 8.68%, and the volatility levels for the past 30 days are at 5.84% for VKTX. The simple moving average for the past 20 days is 19.57% for VKTX’s stock, with a 33.32% simple moving average for the past 200 days.
Analysts’ Opinion of VKTX
Many brokerage firms have already submitted their reports for VKTX stocks, with JP Morgan repeating the rating for VKTX by listing it as a “Overweight.” The predicted price for VKTX in the upcoming period, according to JP Morgan is $80 based on the research report published on September 11, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see VKTX reach a price target of $105. The rating they have provided for VKTX stocks is “Overweight” according to the report published on June 27th, 2024.
Raymond James gave a rating of “Strong Buy” to VKTX, setting the target price at $116 in the report published on May 16th of the current year.
VKTX Trading at 22.84% from the 50-Day Moving Average
After a stumble in the market that brought VKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.51% of loss for the given period.
Volatility was left at 5.84%, however, over the last 30 days, the volatility rate increased by 8.68%, as shares surge +26.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.89% upper at present.
During the last 5 trading sessions, VKTX rose by +18.59%, which changed the moving average for the period of 200-days by +260.08% in comparison to the 20-day moving average, which settled at $65.26. In addition, Viking Therapeutics Inc saw 319.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VKTX starting from Rouan Sarah Kathryn, who sale 11,000 shares at the price of $80.89 back on Oct 25 ’24. After this action, Rouan Sarah Kathryn now owns 0 shares of Viking Therapeutics Inc, valued at $889,790 using the latest closing price.
SINGLETON J MATTHEW, the Director of Viking Therapeutics Inc, sale 16,000 shares at $79.50 during a trade that took place back on Oct 25 ’24, which means that SINGLETON J MATTHEW is holding 9,500 shares at $1,272,000 based on the most recent closing price.
Stock Fundamentals for VKTX
Current profitability levels for the company are sitting at:
- -307.27 for the present operating margin
- 0.29 for the gross margin
The net margin for Viking Therapeutics Inc stands at -227.41. The total capital return value is set at -0.15. Equity return is now at value -15.50, with -15.02 for asset returns.
Based on Viking Therapeutics Inc (VKTX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -60.12. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -5152.62.
Currently, EBITDA for the company is -100.83 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 19716.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 36.47.
Conclusion
In a nutshell, Viking Therapeutics Inc (VKTX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
